The CELx HSP test has the high potential to be developed into a clinical diagnostic test or confirmatory test for better informing physicians about HER2-driven diseases such as breast cancer or HER2-driven cancer in other tissues [41, 42]. Here, ERBB2 is linked to breast cancer.